Fructose-1,6-bisphosphatase-1 (FBP1), a gluconeogenesis regulatory enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate and inorganic phosphate. FBP1 has been reported to be downregulated in human hepatocellular carcinomas. However, the prognostic value of FBP1 expression in hepatocellular carcinoma patients is still unclear. Here, we investigated the prognostic value of FBP1 expression in liver cancer patients. FBP1 mRNA expression was determined in tumor tissues and non-tumor tissues by real-time PCR. For evaluation of the prognostic value of FBP1 expression to each clinicopathologic factor, Kaplan-Meier method and Cox's Proportional Hazard Model (univariate analysis and multivariate analysis all were used) were employed. A simple risk score devised by using significant variables obtained from Cox's regression analysis for further predicting the HCC patients' prognosis. We observed reduced FBP1 mRNA level in cancerous tissues in comparison to non-cancerous tissues. FBP1 expression was also significantly correlated with age, histological grade and tumor stage. More importantly, Kaplan-Meier analysis showed that patients with high FBP1 expression had longer disease-free survival and overall survival compared with those with low expression of FBP1. Cox's regression analysis indicated that FBP1 expression, histological grade, and tumor stage might be significant prognostic factors for disease-free survival and overall survival. Finally, we found that patients whose total score >1 and >2 are more likely to relapse and die than patients whose total score <= 1 and <= 2. FBP1 expression in liver tumors is a potential prognostic tool for patients. The risk scoring system is useful in predicting survival of liver cancer patients after tumor resection.
[1]Fudan Univ, Huashan Hosp, Dept Infect Dis & Hepatol, 12 Middle Urumqi Rd, Shanghai 200040, Peoples R China.
(8.0+极速模式)